Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 in Advanced Malignant Solid Tumors
NCT04758897Phase 1Unknown
- Sponsor
- Virogin Biotech
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VG161 in advanced malignant solid tumor, sponsored by Virogin Biotech. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 month, Occurrence and Numbers of Dose Limiting Toxicities at 1 month and 1 more. Status: unknown.
02
Drugs
VG161
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04758897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758897.